One-carbon Therapeutics to Present Trial-in-Progress Poster on ODIN Phase 1/2 Study ofTH9619 at the 2026 ASCO Annual Meeting
Solna, Sweden, May 29th, 2026. One-carbon Therapeutics AB, a clinical-stage biotechnology company pioneering first-in-class cancer therapies that exploit cancer’s oncogene addition, today announced that a Trial-in-Progress poster on its ongoing ODIN Phase 1/2 clinical study (NCT07151040) of TH9619 will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from […]